Precision Medicine in Oncology® | Specialty

Utilizing Next-Generation ALK Inhibitors in NSCLC

July 16th 2014

Next-Generation ALK Inhibitors in NSCLC

July 16th 2014

Frontline ALK, EGFR Inhibition in NSCLC

July 16th 2014

Afatinib Plus Cetuximab in Resistant NSCLC

July 16th 2014

AZD9291 and Rociletinib in T790M-Mutant NSCLC

July 16th 2014

Next-Generation EGFR Inhibitors in NSCLC

July 16th 2014

Subgroup Analyses for Nab-Paclitaxel in NSCLC

July 16th 2014

Maintenance Nab-Paclitaxel in Squamous NSCLC

July 16th 2014

Nab-Paclitaxel in Non-Small Cell Lung Cancer

July 16th 2014

Introduction: Exploration of Nab-Paclitaxel in NSCLC

July 16th 2014

Novel Therapies, Strategies in Development for NSCLC

July 16th 2014

The treatment landscape for patients with non-small cell lung cancer (NSCLC) is poised to undergo dramatic changes, as novel immunotherapies, second-generation targeted therapies, and new maintenance strategies continue to show promise in clinical trials.

Dr. Diamond on the Ability to Test Urine for BRAF Mutations

July 11th 2014

Eli L. Diamond, MD, neurologist, Memorial Sloan Kettering Cancer Center, discusses the results of an analysis that examined the detection of BRAF mutations in urine and plasma cell-free DNA in patients with Langerhans Cell Histiocytosis(LCH) and Erdheim-Chester Disease (ECD) who have a BRAFV600E mutation

Lost in Translation: Objectivity Can Be Elusive in Clinical Trial Reporting

July 10th 2014

Although oncology researchers seek to describe the significance of clinical trial outcomes with scientific rigor, the terminology used to communicate those findings in the peer-reviewed literature sometimes falls short in conveying the impact that a given therapy may have on patients in a real-world scenario.

Dr. Keefe on the Role of Supportive Care in Personalized Medicine

July 9th 2014

Dorothy M. K. Keefe, MD, FRACP, past president, MASCC, director, SA Cancer Service, professor of cancer medicine, University of Adelaide, Australia, discusses the role of supportive care in personalized medicine.

Communication Challenges Loom as Germline Versus Somatic Cancer Data Evolve

July 8th 2014

Essentially all members of the medical community, including the most "generalist" family practice physicians, are being required to understand and incorporate into their daily practice an ever-increasing quantity of information related to the broad realm of molecular medicine

Dr. Galbraith Discusses the Development of AZD9291

July 1st 2014

Susan Galbraith, MD, PhD, head, Oncology Innovative Medicine, AstraZeneca, discusses the development of AZD9291 for lung cancer.

Dr. Peeters on the Frequency of S492R Mutations Following EGFR Inhibition in mCRC

June 27th 2014

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the frequency of S492R mutations found in patients with metastatic colorectal cancer patients who were treated with panitumumab or cetuximab monotherapy.

Dr. Raftopoulos on Pulmonary Toxicity With EGFR TKIs

June 26th 2014

Haralambos Raftopoulos, MD, associate professor, Hofstra North Shore-LIJ School of Medicine, discusses pulmonary toxicity with EGFR tyrosine kinase inhibitors (TKIs).

ODAC Votes Against Maintenance Olaparib in BRCA-Positive Ovarian Cancer

June 25th 2014

The FDA's Oncologic Drugs Advisory Committee voted 11-2 against the accelerated approval of the PARP inhibitor olaparib as a maintenance therapy for women with platinum-sensitive relapsed ovarian cancer with germline BRCA mutations.

Mutations in Ovarian Cancer More Frequent, Varied Than Estimated

June 24th 2014

Genetic testing limited to BRCA1/2 mutations would have missed 29% of mutations that carry hereditary risk of ovarian cancer, a study using next-generation sequencing showed.